Travere Therapeutics, Inc. (TVTX) Stock Analysis and Metrics

Travere Therapeutics

NASDAQ: TVTX

$57.36 ▲ +0.68 (+1.20%)

At close: Jul 24, 2026 · 4:00 PM UTC

Financial Ratios

Market Cap5.25 Bn

P/E216.90

P/S-74.93

Div. Yield0.00

ROIC (Qtr)-0.01

Add ratio to table…

About

Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering therapies for rare kidney and metabolic diseases. The company’s lead product, FILSPARI (sparsentan), has received full approval in the United States to slow kidney function decline in adults with primary immunoglobulin A nephropathy who are at risk of disease progression. Travere Therapeutics also advances sparsentan for focal segmental glomerulosclerosis and is developing pegtibatinase for classical homocystinuria. In addition, the commercial portfolio includes Thiola and Thiola EC for cystinuria. The company’s strategy centers on leveraging its rare disease expertise to bring innovative treatments to patients with high unmet medical need.

Travere Therapeutics generates revenue primarily from product sales of its approved therapies and from milestone and royalty payments under licensing agreements. Sales of FILSPARI in the United States and Europe contribute the majority of product revenue, supplemented by sales of Thiola and Thiola EC for cystinuria. The company receives regulatory and market access milestone payments from partners such as CSL Vifor and potential future payments from Chugai related to sparsentan development in Asia. Royalties are paid to Ligand Pharmaceuticals and Bristol Myers Squibb based on net sales of sparsentan. Additionally, the company may earn revenue from future sales of pegtibatinase if it receives regulatory approval for homocystinuria.

Travere Therapeutics holds a differentiated position in the rare kidney disease market as the developer of the only oral, once daily, non immunosuppressive therapy approved for immunoglobulin A nephropathy. Competitors in the IgAN space include Calliditas Therapeutics with Tarpeyo, Vertex Pharmaceuticals with povetacicept, and Novartis with atrasentan, which are either immunosuppressive or target different pathways. In focal segmental glomerulosclerosis, there are currently no FDA approved pharmacologic treatments, giving Travere a potential first mover advantage if sparsentan gains approval. The company’s competitive advantages stem from its orphan drug exclusivities, deep expertise in rare disease clinical development, and a diversified pipeline that includes pegtibatinase for homocystinuria and the established cystinuria franchise.

Travere Therapeutics serves patients with rare kidney and metabolic diseases and collaborates with specialty partners for commercialization. Specific partner names include CSL Vifor, which handles commercialization of sparsentan in Europe and certain additional territories; Chugai, which holds rights to develop and commercialize sparsentan in Japan, South Korea, and Taiwan; and Mission Pharmacal, which provides the licence for Thiola and Thiola EC in the United States and Canada. The end user customers are patients treated by nephrologists, urologists, and other healthcare specialists who prescribe the company's therapies.

Investment Thesis

▲ Bull case

The recent FDA approval of Filspari for FSGS expands the addressable patient population to more than 30,000 individuals in the United States without nephrotic syndrome, and when combined with the existing IgA nephropathy cohort the total eligible pool exceeds 100,000 patients. Management has highlighted that this broader indication supports a peak sales potential of 3,000,000,000 dollars for Filspari, a figure that assumes continued penetration in both indications. Early commercial data show record new patient start forms of 993 in the first quarter of fiscal year 2,026, indicating strong physician interest and a faster uptake trajectory compared with the initial IgA nephropathy launch. The company believes that the established payer relationships and high first pass approval rates observed for FSGS will accelerate reimbursement and drive sustained top line growth over the next several years.
Commercial momentum is reinforced by the high conversion of patient start forms into therapy, with management noting that the majority of forms translate into actual prescription fills despite typical quarterly gross to net adjustments and fewer revenue recognition weeks. The launch of Filspari in FSGS has benefited from a halo effect, where physicians already familiar with the drug in IgA nephropathy are quickly adopting it for FSGS patients, and vice versa, creating a reinforcing cycle of demand across both indications. Payer feedback indicates higher first pass approval rates for FSGS than were seen for IgA nephropathy at launch, reducing barriers to access and supporting rapid patient onboarding. This strong early performance suggests that the market may be underestimating the speed at which Filspari can capture share of the progressive glomerular disease landscape.
The pipeline program pegtobatinase for classical homocystinuria has restarted enrollment in the pivotal Phase III HARMONY study, with the first new patient dosed and topline results expected in 2,027. Data from the earlier Phase I II COMPOSE study showed a mean relative reduction in total homocysteine of 67.1% at the 2.5 milligram per kilogram twice weekly dose, maintaining levels below the clinically meaningful threshold of 100 micromoles. If the Phase III trial confirms these findings, pegtobatinase could become the first disease modifying therapy for HCU, addressing an unmet need in a patient population estimated at 7,000 to 10,000 individuals globally. Success in this program would add a new revenue stream and diversify the company’s reliance on Filspari alone.
Intellectual property protection has been strengthened by a Notice of Allowance from the USPTO for a patent application covering specific methods of using sparsentan in IgA nephropathy, with the expected issuance date extending exclusivity into October 2,037. This long dated patent coverage shields the core product from generic competition for over a decade beyond the current expiration horizon, providing a durable moat around Filspari’s commercial franchise. The extension of exclusivity supports the company’s long term peak sales assumptions and reduces the risk of near term erosion from biosimilar or generic entrants.
The recent underwritten offering of 475,000,000 dollars in zero point five% convertible senior notes due 2,032 has provided substantial liquidity at a minimal coupon cost, with net proceeds estimated at 460,000,000 dollars. A portion of these proceeds is being used to repurchase approximately 221,400,000 dollars of the higher coupon two point twenty five% senior convertible notes due 2,029, thereby lowering overall interest expense and extending the cash runway. The strengthened balance sheet positions the company to fund continued commercialization investments in FSGS and IgA nephropathy, advance the pegtobatinase program, and pursue additional pipeline opportunities without immediate reliance on equity dilution.

The recent FDA approval of Filspari for FSGS expands the addressable patient population to more than 30,000 individuals in the United States without nephrotic syndrome, and when combined with the existing IgA nephropathy cohort the total eligible pool exceeds 100,000 patients. Management has highlighted that this broader indication supports a peak sales potential of 3,000,000,000 dollars for Filspari, a figure that assumes continued penetration in both indications. Early commercial data show record new patient start forms of 993 in the first quarter of fiscal year 2,026, indicating strong physician interest and a faster uptake trajectory compared with the initial IgA nephropathy launch. The company believes that the established payer relationships and high first pass approval rates observed for FSGS will accelerate reimbursement and drive sustained top line growth over the next several years.
Commercial momentum is reinforced by the high conversion of patient start forms into therapy, with management noting that the majority of forms translate into actual prescription fills despite typical quarterly gross to net adjustments and fewer revenue recognition weeks. The launch of Filspari in FSGS has benefited from a halo effect, where physicians already familiar with the drug in IgA nephropathy are quickly adopting it for FSGS patients, and vice versa, creating a reinforcing cycle of demand across both indications. Payer feedback indicates higher first pass approval rates for FSGS than were seen for IgA nephropathy at launch, reducing barriers to access and supporting rapid patient onboarding. This strong early performance suggests that the market may be underestimating the speed at which Filspari can capture share of the progressive glomerular disease landscape.
The pipeline program pegtobatinase for classical homocystinuria has restarted enrollment in the pivotal Phase III HARMONY study, with the first new patient dosed and topline results expected in 2,027. Data from the earlier Phase I II COMPOSE study showed a mean relative reduction in total homocysteine of 67.1% at the 2.5 milligram per kilogram twice weekly dose, maintaining levels below the clinically meaningful threshold of 100 micromoles. If the Phase III trial confirms these findings, pegtobatinase could become the first disease modifying therapy for HCU, addressing an unmet need in a patient population estimated at 7,000 to 10,000 individuals globally. Success in this program would add a new revenue stream and diversify the company’s reliance on Filspari alone.
Intellectual property protection has been strengthened by a Notice of Allowance from the USPTO for a patent application covering specific methods of using sparsentan in IgA nephropathy, with the expected issuance date extending exclusivity into October 2,037. This long dated patent coverage shields the core product from generic competition for over a decade beyond the current expiration horizon, providing a durable moat around Filspari’s commercial franchise. The extension of exclusivity supports the company’s long term peak sales assumptions and reduces the risk of near term erosion from biosimilar or generic entrants.
The recent underwritten offering of 475,000,000 dollars in zero point five% convertible senior notes due 2,032 has provided substantial liquidity at a minimal coupon cost, with net proceeds estimated at 460,000,000 dollars. A portion of these proceeds is being used to repurchase approximately 221,400,000 dollars of the higher coupon two point twenty five% senior convertible notes due 2,029, thereby lowering overall interest expense and extending the cash runway. The strengthened balance sheet positions the company to fund continued commercialization investments in FSGS and IgA nephropathy, advance the pegtobatinase program, and pursue additional pipeline opportunities without immediate reliance on equity dilution.

▼ Bear case

The boxed warning for hepatotoxicity and embryo fetal toxicity associated with Filspari imposes a significant prescribing burden through the required REMS program, which mandates regular liver function testing and pregnancy prevention measures. This regulatory complexity may deter physicians, especially those in community practices with limited resources, from initiating therapy despite clinical efficacy. Patient adherence could also be affected by the need for frequent laboratory monitoring and concerns about liver safety, potentially limiting the real world uptake that management projects.
Competitive pressures are mounting from multiple fronts, including emerging endothelin receptor antagonists with potentially improved safety profiles, complement inhibitors targeting alternative pathways in IgA nephropathy, and B cell directed therapies that could replace steroids in treatment regimens. Generic renin angiotensin system inhibitors remain low cost alternatives that payers may favor, especially if safety concerns around Filspari lead to preferential formulary placement for cheaper options. These competitive dynamics could erode market share and constrain the ability to achieve the projected three billion dollar peak sales.
The estimated eligible patient population for FSGS may be overstated, as the criteria for exclusion of active nephrotic syndrome require a nuanced clinical assessment that many physicians may not consistently apply, leading to underdiagnosis of the treatable cohort. Furthermore, the progressive nature of FSGS means that a subset of patients may present with nephrotic syndrome at initial diagnosis, delaying eligibility until after immunosuppressive induction, which could slow the conversion of patient start forms into sustained therapy. These factors suggest that the addressable market could be smaller than the 30,000 figure cited by management.
The pegtobatinase program relies on reduction of plasma total homocysteine as a surrogate endpoint for efficacy in classical homocystinuria, and there is uncertainty whether the FDA will accept this marker as sufficient for approval without demonstrated clinical outcomes such as neurocognitive improvement or reduction in complications. If the HARMONY study fails to meet its primary endpoint or if regulatory feedback demands additional data, the timeline for potential approval could extend beyond 2,027, delaying any near term contribution to earnings and increasing development costs.
Although the company reported non GAAP net income in the first quarter of fiscal year 2,026, GAAP results remain negative, reflecting ongoing losses that are masked by adjustments for stock based compensation, depreciation and royalty expenses. Continued investment in commercialization efforts for FSGS, higher SG&A spend related to expanded field teams, and ongoing R&D expenditures for the pegtobatinase trial could strain cash flow if revenue growth does not accelerate as anticipated. Dependence on milestone payments and licensing revenue adds variability to the top line, making financial performance less predictable.

The boxed warning for hepatotoxicity and embryo fetal toxicity associated with Filspari imposes a significant prescribing burden through the required REMS program, which mandates regular liver function testing and pregnancy prevention measures. This regulatory complexity may deter physicians, especially those in community practices with limited resources, from initiating therapy despite clinical efficacy. Patient adherence could also be affected by the need for frequent laboratory monitoring and concerns about liver safety, potentially limiting the real world uptake that management projects.
Competitive pressures are mounting from multiple fronts, including emerging endothelin receptor antagonists with potentially improved safety profiles, complement inhibitors targeting alternative pathways in IgA nephropathy, and B cell directed therapies that could replace steroids in treatment regimens. Generic renin angiotensin system inhibitors remain low cost alternatives that payers may favor, especially if safety concerns around Filspari lead to preferential formulary placement for cheaper options. These competitive dynamics could erode market share and constrain the ability to achieve the projected three billion dollar peak sales.
The estimated eligible patient population for FSGS may be overstated, as the criteria for exclusion of active nephrotic syndrome require a nuanced clinical assessment that many physicians may not consistently apply, leading to underdiagnosis of the treatable cohort. Furthermore, the progressive nature of FSGS means that a subset of patients may present with nephrotic syndrome at initial diagnosis, delaying eligibility until after immunosuppressive induction, which could slow the conversion of patient start forms into sustained therapy. These factors suggest that the addressable market could be smaller than the 30,000 figure cited by management.
The pegtobatinase program relies on reduction of plasma total homocysteine as a surrogate endpoint for efficacy in classical homocystinuria, and there is uncertainty whether the FDA will accept this marker as sufficient for approval without demonstrated clinical outcomes such as neurocognitive improvement or reduction in complications. If the HARMONY study fails to meet its primary endpoint or if regulatory feedback demands additional data, the timeline for potential approval could extend beyond 2,027, delaying any near term contribution to earnings and increasing development costs.
Although the company reported non GAAP net income in the first quarter of fiscal year 2,026, GAAP results remain negative, reflecting ongoing losses that are masked by adjustments for stock based compensation, depreciation and royalty expenses. Continued investment in commercialization efforts for FSGS, higher SG&A spend related to expanded field teams, and ongoing R&D expenditures for the pegtobatinase trial could strain cash flow if revenue growth does not accelerate as anticipated. Dependence on milestone payments and licensing revenue adds variability to the top line, making financial performance less predictable.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password